| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| HCMHUTCHMED (China) Limited | 2.63B | 15.31 | 69.59 | -24.8% | 77.53% | 37.59% | 0.12 | |
| SHPHShuttle Pharmaceuticals Holdings, Inc. | 2.85M | 1.48 | -0.00 | -7.68% | 1.65 | |||
| BGMSBio Green Med Solution, Inc. | 7.01M | 1.43 | -0.00 | -89.76% | -67.15% | -76.65% | ||
| SBFMSunshine Biopharma, Inc. | 5.99M | 1.22 | -0.17 | 44.75% | -17.35% | -24.55% | 0.04 | |
| RNTXRein Therapeutics Inc. | 30.49M | 1.16 | -0.33 | -127.48% | ||||
| CGEMCullinan Therapeutics, Inc. | 629.75M | 10.66 | -3.43 | -48.03% | 0.00 | |||
| ONCBeOne Medicines Ltd. | 34.44B | 338.29 | -55.28 | 54.96% | 1.38% | 1.66% | 0.32 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 8.82M | 1.07M | 238.39M | 198.22M | 428.21M | 308.87M | 1.18B | 1.42B | 2.46B | 3.81B |
| Revenue Growth % | -0.32% | -0.88% | 221.79% | -0.17% | 1.16% | -0.28% | 2.81% | 0.2% | 0.74% | 0.55% |
| Cost of Goods Sold | 58.25M | 98.03M | 273.99M | 707.71M | 71.19M | 70.66M | 164.91M | 286.48M | 379.92M | 594.09M |
| COGS % of Revenue | 6.61% | 91.62% | 1.15% | 3.57% | 0.17% | 0.23% | 0.14% | 0.2% | 0.15% | 0.16% |
| Gross Profit | -49.43M | -96.96M | -35.6M | -509.49M | 357.02M | 238.22M | 1.01B | 1.13B | 2.08B | 3.22B |
| Gross Margin % | -5.61% | -90.62% | -0.15% | -2.57% | 0.83% | 0.77% | 0.86% | 0.8% | 0.85% | 0.84% |
| Gross Profit Growth % | -4.6% | -0.96% | 0.63% | -13.31% | 1.7% | -0.33% | 3.25% | 0.12% | 0.84% | 0.55% |
| Operating Expenses | 7.31M | 20.1M | 62.85M | 196.28M | 1.32B | 1.9B | 2.45B | 2.92B | 3.29B | 3.78B |
| OpEx % of Revenue | 0.83% | 18.78% | 0.26% | 0.99% | 3.08% | 6.14% | 2.08% | 2.06% | 1.34% | 0.99% |
| Selling, General & Admin | 7.31M | 20.1M | 62.6M | 195.38M | 388.25M | 600.18M | 990.12M | 1.28B | 1.51B | 1.83B |
| SG&A % of Revenue | 0.83% | 18.78% | 0.26% | 0.99% | 0.91% | 1.94% | 0.84% | 0.9% | 0.61% | 0.48% |
| Research & Development | 58.25M | 98.03M | 269.02M | 679M | 927.34M | 1.29B | 1.46B | 1.64B | 1.78B | 1.95B |
| R&D % of Revenue | 6.61% | 91.62% | 1.13% | 3.43% | 2.17% | 4.19% | 1.24% | 1.16% | 0.72% | 0.51% |
| Other Operating Expenses | -916K | -2.49M | 11.46M | 1.99M | 1.33M | 846K | 750K | 0 | 0 | 0 |
| Operating Income | -56.74M | -117.06M | -98.46M | -705.77M | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B | -568.2M |
| Operating Margin % | -6.44% | -109.4% | -0.41% | -3.56% | -2.24% | -5.37% | -1.22% | -1.26% | -0.49% | -0.15% |
| Operating Income Growth % | -2.6% | -1.06% | 0.16% | -6.17% | -0.36% | -0.73% | 0.13% | -0.24% | 0.33% | 0.53% |
| EBITDA | -55.2M | -115.15M | -93.7M | -695.38M | -941.27M | -1.63B | -1.39B | -1.72B | -1.12B | -396.44M |
| EBITDA Margin % | -6.26% | -107.62% | -0.39% | -3.51% | -2.2% | -5.26% | -1.18% | -1.22% | -0.46% | -0.1% |
| EBITDA Growth % | -2.89% | -1.09% | 0.19% | -6.42% | -0.35% | -0.73% | 0.14% | -0.24% | 0.35% | 0.65% |
| D&A (Non-Cash Add-back) | 1.54M | 1.91M | 4.76M | 10.39M | 18.62M | 31.79M | 46.46M | 66.28M | 87.67M | 171.76M |
| EBIT | -56.74M | -117.06M | -98.46M | -705.77M | -959.89M | -1.66B | -1.44B | -1.79B | -1.21B | -568.2M |
| Net Interest Income | 559K | 383K | -4.11M | 13.95M | 9.13M | 2M | 15.76M | 52.48M | 74.01M | 47.84M |
| Interest Income | 559K | 0 | 0 | 13.95M | 9.13M | 2M | 15.76M | 52.48M | 74.01M | 47.84M |
| Interest Expense | 0 | 383K | 4.11M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | -357K | -2.1M | 7.39M | 15.94M | 16.3M | 39.49M | 147K | -171.37M | 381.9M | 35.2M |
| Pretax Income | -57.1M | -119.16M | -91.06M | -689.83M | -943.59M | -1.62B | -1.44B | -1.96B | -825.84M | -533M |
| Pretax Margin % | -6.48% | -111.37% | -0.38% | -3.48% | -2.2% | -5.24% | -1.22% | -1.38% | -0.34% | -0.14% |
| Income Tax | 0 | 54K | 2.23M | -15.8M | 6.99M | 10.4M | 19.23M | 42.78M | 55.87M | 111.78M |
| Effective Tax Rate % | 1% | 1% | 1.02% | 0.98% | 1.01% | 1% | 1.01% | 1.02% | 1.07% | 1.21% |
| Net Income | -57.1M | -119.22M | -93.11M | -673.77M | -948.63M | -1.62B | -1.46B | -2B | -881.71M | -644.79M |
| Net Margin % | -6.48% | -111.42% | -0.39% | -3.4% | -2.22% | -5.26% | -1.24% | -1.42% | -0.36% | -0.17% |
| Net Income Growth % | -2.12% | -1.09% | 0.22% | -6.24% | -0.41% | -0.71% | 0.1% | -0.37% | 0.56% | 0.27% |
| Net Income (Continuing) | -57.1M | -119.22M | -93.3M | -674.03M | -950.58M | -1.63B | -1.46B | -2B | -881.71M | -644.79M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 14.42M | 14.45M | 16.15M | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.82 | -3.90 | -2.21 | -12.09 | -15.86 | -19.11 | -15.21 | -19.37 | -8.45 | -6.12 |
| EPS Growth % | -4.2% | -1.14% | 0.43% | -4.47% | -0.31% | -0.2% | 0.2% | -0.27% | 0.56% | 0.28% |
| EPS (Basic) | -1.82 | -3.90 | -2.21 | -12.09 | -15.86 | -19.11 | -15.21 | -19.37 | -8.45 | -6.12 |
| Diluted Shares Outstanding | 31.52M | 31.05M | 41.78M | 55.44M | 60.05M | 83.47M | 92.79M | 103.13M | 104.39M | 105.29M |
| Basic Shares Outstanding | 31.52M | 31.05M | 41.78M | 55.44M | 60.05M | 83.47M | 92.79M | 103.13M | 104.39M | 105.29M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 106.27M | 374.4M | 913.5M | 1.94B | 1.17B | 4.96B | 7.61B | 5.21B | 4.2B | 3.99B |
| Cash & Short-Term Investments | 100.49M | 368.17M | 837.52M | 1.81B | 982.74M | 4.65B | 6.62B | 4.53B | 3.17B | 2.63B |
| Cash Only | 17.87M | 87.51M | 239.6M | 712.94M | 618.01M | 1.38B | 4.38B | 3.87B | 3.17B | 2.63B |
| Short-Term Investments | 82.62M | 280.66M | 597.91M | 1.07B | 364.73M | 3.27B | 2.24B | 665.25M | 2.6M | 0 |
| Accounts Receivable | 0 | 0 | 29.43M | 49.67M | 70.88M | 79.67M | 500.18M | 198.98M | 395.89M | 709.11M |
| Days Sales Outstanding | - | - | 45.06 | 91.46 | 60.42 | 94.15 | 155.2 | 51.29 | 58.77 | 67.93 |
| Inventory | 0 | 0 | 10.93M | 16.24M | 28.55M | 89.29M | 242.63M | 282.35M | 416.12M | 494.99M |
| Days Inventory Outstanding | - | - | 14.56 | 8.38 | 146.39 | 461.27 | 537.02 | 359.74 | 399.78 | 304.11 |
| Other Current Assets | 0 | 0 | 25.73M | 86.01M | 76.49M | 307K | 328K | 196K | 56.25M | 25.19M |
| Total Non-Current Assets | 10.49M | 31.41M | 132.98M | 305.84M | 439.59M | 640.07M | 921.64M | 1.17B | 1.6B | 1.93B |
| Property, Plant & Equipment | 6.61M | 25.98M | 62.57M | 194.24M | 324.92M | 446.3M | 662.51M | 923.98M | 1.37B | 1.66B |
| Fixed Asset Turnover | 1.33x | 0.04x | 3.81x | 1.02x | 1.32x | 0.69x | 1.78x | 1.53x | 1.79x | 2.30x |
| Goodwill | 0 | 0 | 109K | 109K | 109K | 109K | 109K | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 19.71M | 52.23M | 5.85M | 53.73M | 103.35M | 94.57M | 108.86M | 129.76M |
| Long-Term Investments | 0 | 0 | 0 | 16.49M | 0 | 49.34M | 100.79M | 91.78M | 89.64M | 128.93M |
| Other Non-Current Assets | 3.88M | 4.67M | 42.91M | 13.23M | 108.72M | 24.62M | -55.53M | 61.89M | 31.57M | 13.38M |
| Total Assets | 116.76M | 405.81M | 1.05B | 2.25B | 1.61B | 5.6B | 8.54B | 6.38B | 5.81B | 5.92B |
| Asset Turnover | 0.08x | 0.00x | 0.23x | 0.09x | 0.27x | 0.06x | 0.14x | 0.22x | 0.42x | 0.64x |
| Asset Growth % | 1.18% | 2.48% | 1.58% | 1.15% | -0.28% | 2.47% | 0.52% | -0.25% | -0.09% | 0.02% |
| Total Current Liabilities | 35.17M | 35.06M | 149.99M | 246.45M | 310.31M | 1.08B | 1.6B | 1.47B | 1.81B | 2.21B |
| Accounts Payable | 8.98M | 11.96M | 69.78M | 113.28M | 122.49M | 231.96M | 262.4M | 294.78M | 315.11M | 405M |
| Days Payables Outstanding | 56.27 | 44.52 | 92.96 | 58.43 | 628.01 | 1.2K | 580.79 | 375.58 | 302.74 | 248.82 |
| Short-Term Debt | 14.6M | 0 | 9.22M | 8.73M | 0 | 335.01M | 427.56M | 328.97M | 688.37M | 851.53M |
| Deferred Revenue (Current) | 1000K | 0 | 1000K | 1000K | 0 | 0 | 1000K | 1000K | 0 | 0 |
| Other Current Liabilities | 5.87M | 804K | 31.22M | 49.22M | 56.86M | 234.57M | 260.77M | 299.11M | 285.81M | 359.5M |
| Current Ratio | 3.02x | 10.68x | 6.09x | 7.89x | 3.78x | 4.61x | 4.76x | 3.55x | 2.32x | 1.80x |
| Quick Ratio | 3.02x | 10.68x | 6.02x | 7.82x | 3.69x | 4.53x | 4.61x | 3.35x | 2.09x | 1.58x |
| Cash Conversion Cycle | - | - | -33.34 | 41.41 | -421.2 | -642.82 | 111.44 | 35.45 | 155.81 | 123.22 |
| Total Non-Current Liabilities | 7.27M | 17.85M | 212.26M | 249.59M | 323.62M | 656.32M | 803.41M | 527.41M | 457.83M | 373.79M |
| Long-Term Debt | 6.19M | 17.28M | 155.49M | 189.67M | 240.69M | 183.64M | 202.11M | 209.15M | 197.62M | 166.48M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 25.83M | 29.42M | 43.04M | 34.52M | 22.25M | 44.28M |
| Deferred Tax Liabilities | 0 | -564K | 0 | 11.14M | 0 | 10.79M | 14.17M | 16M | 16.49M | 42.01M |
| Other Non-Current Liabilities | 1.08M | 0 | 56.77M | 59.91M | 57.09M | 383.33M | 277.44M | 187.54M | 187.27M | 90.7M |
| Total Liabilities | 116.76M | 405.81M | 362.25M | 496.04M | 633.93M | 1.73B | 2.4B | 2B | 2.27B | 2.59B |
| Total Debt | 20.79M | 17.28M | 164.72M | 198.4M | 277.34M | 561.96M | 694.64M | 596.67M | 930.18M | 1.08B |
| Net Debt | 2.92M | -70.23M | -74.89M | -514.54M | -340.67M | -819.99M | -3.68B | -3.27B | -2.24B | -1.55B |
| Debt / Equity | - | 0.05x | 0.24x | 0.11x | 0.28x | 0.15x | 0.11x | 0.14x | 0.26x | 0.32x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | -305.64x | -23.97x | - | - | - | - | - | - | - |
| Total Equity | -101.77M | 352.91M | 698.65M | 1.77B | 978.35M | 3.87B | 6.13B | 4.38B | 3.54B | 3.33B |
| Equity Growth % | -4.95% | 4.47% | 0.98% | 1.53% | -0.45% | 2.95% | 0.58% | -0.29% | -0.19% | -0.06% |
| Book Value per Share | -3.23 | 11.37 | 16.72 | 31.89 | 16.29 | 46.35 | 66.09 | 42.50 | 33.89 | 31.65 |
| Total Shareholders' Equity | -101.77M | 352.91M | 684.23M | 1.75B | 962.21M | 3.87B | 6.13B | 4.38B | 3.54B | 3.33B |
| Common Stock | 12K | 52K | 59K | 77K | 79K | 118K | 133K | 135K | 135K | 138K |
| Retained Earnings | -118.19M | -237.41M | -330.52M | -1.01B | -1.96B | -3.55B | -5.08B | -7.08B | -7.96B | -8.61B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.81M | -946K | -480K | 1.53M | -8M | 6.94M | 17.95M | -77.42M | -99.45M | -148.99M |
| Minority Interest | 0 | 0 | 14.42M | 14.45M | 16.15M | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -39.84M | -89.51M | 12.75M | -547.72M | -750.27M | -1.28B | -1.3B | -1.5B | -1.16B | -140.63M |
| Operating CF Margin % | -4.52% | -83.66% | 0.05% | -2.76% | -1.75% | -4.16% | -1.1% | -1.06% | -0.47% | -0.04% |
| Operating CF Growth % | -3.58% | -1.25% | 1.14% | -43.95% | -0.37% | -0.71% | -0.01% | -0.15% | 0.23% | 0.88% |
| Net Income | -57.1M | -119.22M | -93.3M | -674.03M | -950.58M | -1.6B | -1.41B | -2B | -881.71M | -644.79M |
| Depreciation & Amortization | 1.54M | 1.91M | 4.76M | 10.39M | 18.62M | 31.79M | 46.46M | 66.28M | 87.67M | 171.76M |
| Stock-Based Compensation | 10.21M | 10.63M | 42.86M | 87.13M | 134.15M | 183.48M | 240.71M | 303.16M | 367.62M | 441.62M |
| Deferred Taxes | 2.15M | 2.93M | -5.84M | -21.95M | -9.23M | -27.81M | -41.09M | 2.06M | 689K | 25.98M |
| Other Non-Cash Items | 1.09M | 121K | 7.08M | 67.96M | 67.6M | -20.98M | -13.11M | 3.31M | -361.19M | 21.96M |
| Working Capital Changes | 2.26M | 14.12M | 57.2M | -17.21M | -10.83M | 150.58M | -118.34M | 132.39M | -370.54M | -157.17M |
| Change in Receivables | 0 | 0 | -29.43M | -11.63M | -29.82M | 10.36M | -423.02M | 304.11M | -188.31M | -329.44M |
| Change in Inventory | 0 | 0 | -10.93M | -5.31M | -12.31M | -58.91M | -153.33M | -56.69M | -140.95M | -91.5M |
| Change in Payables | 6.19M | 2.71M | 55.3M | 23.47M | 2.22M | 95.83M | 20.01M | -4.35M | 21.48M | 121.5M |
| Cash from Investing | -58.91M | -221.85M | -356.32M | -637.61M | 554.16M | -3.17B | 640.66M | 1.08B | 60M | -548.35M |
| Capital Expenditures | -5.31M | -23.5M | -58.73M | -140.84M | -158.61M | -229.03M | -314.85M | -469.1M | -561.9M | -492.66M |
| CapEx % of Revenue | 0.6% | 21.96% | 0.25% | 0.71% | 0.37% | 0.74% | 0.27% | 0.33% | 0.23% | 0.13% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 1K | 4K | -329.86M | -108.85M | -69M | -109.5M | -51.91M | 1.4B | -36.44M | -39.34M |
| Cash from Financing | 103.2M | 380.9M | 490.36M | 1.69B | 85.68M | 5.2B | 3.64B | -18.97M | 416.48M | 193.45M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 77K | -23K | 18.48M | 29.66M | 51M | 681.21M | 92.76M | 46.96M | 55.71M | 48.37M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -45.16M | -113.02M | -45.98M | -688.55M | -908.88M | -1.51B | -1.61B | -1.97B | -1.75B | -669.77M |
| FCF Margin % | -5.12% | -105.62% | -0.19% | -3.47% | -2.12% | -4.9% | -1.37% | -1.39% | -0.71% | -0.18% |
| FCF Growth % | -3.83% | -1.5% | 0.59% | -13.98% | -0.32% | -0.66% | -0.07% | -0.22% | 0.11% | 0.62% |
| FCF per Share | -1.43 | -3.64 | -1.10 | -12.42 | -15.13 | -18.12 | -17.39 | -19.06 | -16.80 | -6.36 |
| FCF Conversion (FCF/Net Income) | 0.70x | 0.75x | -0.14x | 0.81x | 0.79x | 0.79x | 0.89x | 0.75x | 1.31x | 0.22x |
| Interest Paid | 0 | 826K | 1.26M | 2.21M | 4.32M | 44.13M | 29.97M | 25.17M | 19.75M | 51.17M |
| Taxes Paid | 0 | 25K | 29.29M | 12K | 8.98M | 10.6M | 15.7M | 29.5M | 56M | 69.43M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -94.94% | -17.71% | -54.63% | -69.08% | -67.04% | -29.15% | -38.11% | -22.26% | -18.77% |
| Return on Invested Capital (ROIC) | - | -95.52% | -16.29% | -56.39% | -76.13% | -67.44% | -39.23% | -75.37% | -75.29% | -27.67% |
| Gross Margin | -560.73% | -9061.96% | -14.94% | -257.03% | 83.38% | 77.12% | 85.98% | 79.77% | 84.55% | 84.41% |
| Net Margin | -647.71% | -11141.78% | -39.06% | -339.91% | -221.53% | -526.1% | -123.93% | -141.52% | -35.86% | -16.92% |
| Debt / Equity | - | 0.05x | 0.24x | 0.11x | 0.28x | 0.15x | 0.11x | 0.14x | 0.26x | 0.32x |
| Interest Coverage | - | -305.64x | -23.97x | - | - | - | - | - | - | - |
| FCF Conversion | 0.70x | 0.75x | -0.14x | 0.81x | 0.79x | 0.79x | 0.89x | 0.75x | 1.31x | 0.22x |
| Revenue Growth | -32.37% | -87.86% | 22179.16% | -16.85% | 116.03% | -27.87% | 280.83% | 20.37% | 73.65% | 54.96% |
BeOne Medicines Ltd. (ONC) reported $4.97B in revenue for fiscal year 2024. This represents a 44506% increase from $11.1M in 2013.
BeOne Medicines Ltd. (ONC) grew revenue by 55.0% over the past year. This is strong growth.
Yes, BeOne Medicines Ltd. (ONC) is profitable, generating $68.5M in net income for fiscal year 2024 (-16.9% net margin).
BeOne Medicines Ltd. (ONC) has a return on equity (ROE) of -18.8%. Negative ROE indicates the company is unprofitable.
BeOne Medicines Ltd. (ONC) generated $464.6M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.